ARS Pharmaceuticals, Inc. (SPRY)
(Real Time Quote from BATS)
$13.25 USD
+0.25 (1.92%)
Updated Aug 15, 2024 10:02 AM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SPRY 13.25 +0.25(1.92%)
Will SPRY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SPRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRY
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
SPRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know
Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why
Other News for SPRY
Raymond James ups ARS to strong buy, cites FDA neffy approval
Starbucks picks new CEO, Baxter divests Kidney Care segment: Morning Buzz
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
Raymond James upgrades ARS Pharmaceuticals to Strong Buy on tailwinds
Starbucks picks new CEO, Google unveils Pixel 9: Tuesday Buzz